Identification of predictive biomarkers for severe progression of COVID-19

Identification of predictive biomarkers for severe progression of COVID-19 - PreBiSe-COV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021591

Enrollment

100

Registered

2020-04-27

Start date

2020-04-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Serum is taken from hospitalized patients with COVID-19 at the following time points: within 24 hours of hospital admission, as well as on days 7, 10, 14, and 21 after onset of symptoms of CO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalized patient due to clinical suspicion of COVID-19

Exclusion criteria

Exclusion criteria: Patients under 18 years of age, immunosuppression, 2 x negative SARS-CoV-2 PCR during clinical course AND no typical signs of COVID-19 on chest CT

Design outcomes

Primary

Measure	Time frame
Invasive or non-invasive ventilation within 30 days of onset of COVID-19 related symptoms	—

Secondary

Measure	Time frame
Death of all causes within 1 year after onset of COVID-19 related symptoms	—

Countries

Germany

Contacts

Public ContactChristian Zobel

Bundeswehrkrankenhaus Berlin, Klinik I (Innere Medizin)

ChristianZobel@bundeswehr.org+493028412806

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026